BEIJING — Drug researchers in China are making progress on developing therapies to treat COVID-19 with several antibody drugs, which neutralize the virus, emerging as promising candidates in clinical trials. Xie added that a new drug based on DXP-604 has demonstrated good efficacy in Phase 2 clinical trials. As of Nov 2, the medication had been administered to 14 patients with COVID-19 at Beijing Ditan Hospital through the compassionate use program, which expands access to experimental drugs for critical patients. The company said results from Phase 3 clinical trials overseas have shown that the medication can cut the risk of hospitalization and death of COVID-19 patients by 78 percent. ADVERTISEMENT“Vaccines and antibody therapies are two weapons that complement each other,” said Zhang Linqi, a professor at Tsinghua University’s School of Medicine.

Source: Philippine Daily Inquirer November 09, 2021 08:50 UTC